Evogene
EVGN
26 hedge funds and large institutions have $33.6M invested in Evogene in 2018 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
17% more capital invested
Capital invested by funds: $28.8M → $33.6M (+$4.8M)
8% more funds holding
Funds holding: 24 → 26 (+2)
0.01% less ownership
Funds ownership: 3.58% → 3.57% (-0.01%)
43% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EMG
ETF Managers Group
Summit,
New Jersey
|
+$131K |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$114K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$101K |
| 4 |
BOS
Bingham Osborn & Scarborough
San Francisco,
California
|
+$93.1K |
| 5 |
Morgan Stanley
New York
|
+$32.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$262K |
| 2 |
HIIFS
Harel Insurance Investments & Financial Services
Ramat Gan,
Israel
|
-$218K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$17.5K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$9.46K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$6.41K |
EVGN Hedge Fund Activity: Q1 2018 in Review
26 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Evogene (EVGN) for Q1 2018, worth a combined $33.6M — up 17% from $28.8M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new EVGN positions and 1 closed out — a net gain of 2 holders — while 4 added to existing stakes and 7 trimmed.
The largest buyer was ETF Managers Group, opening a new position worth an estimated $131K. The largest seller was Jane Street, exiting entirely with an estimated $262K sold.
- 26 institutional investors held Evogene (EVGN) as of Q1 2018, up from 24 in Q4 2017.
- Funds reported $33.6M of Evogene stock for Q1 2018, up 17% quarter-over-quarter.
- 3 funds opened new Evogene positions in Q1 2018 and 1 closed out, a net change of +2 holders.
- The largest Evogene buyer in Q1 2018 was ETF Managers Group, an estimated $131K added.
- The largest Evogene seller in Q1 2018 was Jane Street, an estimated $262K sold.
Based on aggregated 13F filings for Q1 2018.